ProteinLogic, founded in 2003, is a Health Care startup based in the United Kingdom. The company has developed ImmiPrint® - a cutting-edge technology platform designed for the diagnosis of tuberculosis (TB), a global health challenge. The last investment round saw a significant injection of $1.35M in grant funding on 24 January 2024, with the Bill & Melinda Gates Foundation stepping in as investors. ProteinLogic's focus on TB diagnosis is particularly poignant, given the disease's status as one of the most significant infectious diseases worldwide, alongside HIV/AIDS. Their ImmiPrint® platform holds the potential to revolutionize TB diagnostics by offering an effective blood-based diagnostic tool, as well as providing valuable insights into disease progression. Additionally, the platform may have the capability to predict which individuals are likely to respond positively to anti-microbial therapy. Overall, ProteinLogic's groundbreaking approach to tackling TB and their recent injection of funding from a prominent global player indicate a promising trajectory for the company as it continues to address a critical global health issue.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Grant | $1.35M | 1 |
|
24 Jan 2024 |
| Grant | €3.58M | 1 | Horizon 2020 | 01 Jul 2015 |
No recent news or press coverage available for ProteinLogic Ltd.
We care about your data, and we'd love to use cookies make your experience better.